AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight (AMAZE 2)
Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)
Sponsor: Novo Nordisk A/S
A observational or N/A phase clinical study on Diabetes Mellitus and Obesity, this trial is actively recruiting participants. The trial is conducted by Novo Nordisk A/S and has accumulated 2 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
2 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Apr 17, 2026 — Apr 28, 2026 [daily]
Not Yet Recruiting
First recorded
Apr 2026
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.
Contact Information
- Novo Nordisk A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bacau, Romania , Balatonfüred, Hungary , Birmingham, United States , Bologna, Italy , Bucharest, Romania , Bucharest, Romania , Bucharest, Romania , Budapest, Hungary , Budapest, Hungary , Budapest, Hungary and 63 more locations